Ravulizumab for reducing nerve damage markers in NMOSD
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a medicine called ravulizumab to see if it lowers certain proteins in the blood that may indicate nerve damage in people with NMOSD. If you have NMOSD, this study could help track how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of NMOSD and test positive for AQP4 antibodies.
- You must have had at least one NMOSD attack (relapse) in the past.
- You can be untreated or on certain medications (like rituximab, steroids, azathioprine, mycophenolate, or ravulizumab).
- You must be vaccinated against meningococcal bacteria or be willing to get vaccinated before starting the study drug.
- You must weigh at least 40 kg (about 88 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This study follows people with NMOSD (a rare autoimmune disease affecting the brain and spinal cord) to learn more about the condition and how it affects patients over time. It involves regular check-ups and MRI scans, with the goal of improving future care and treatment.
This study looks at how well ravulizumab (Ultomiris) works for people with neuromyelitis optica spectrum disorder (NMOSD) by tracking symptoms and MRI scans over time. It aims to see if the drug helps control the disease in real-world use.
Hear when a new NMOSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.